Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  title={Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid $\beta$-peptide},
  author={Christian Haass and Dennis J. Selkoe},
  journal={Nature Reviews Molecular Cell Biology},
  • C. Haass, D. Selkoe
  • Published 1 February 2007
  • Biology
  • Nature Reviews Molecular Cell Biology
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates — soluble oligomers — in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid β-protein oligomers adversely affect synaptic structure and plasticity. Findings in… 
Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease
β-amyloid oligomers and cellular prion protein in Alzheimer’s disease
The importance of A β oligomers in AD, commonalities between AD and CJD, and the newly emergent role of PrPC as a receptor for Aβ oligomers are reviewed to suggest mechanistic similarities between the two neurodegenerative diseases.
Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease.
The emerging trend of defining several human neurodegenerative disorders as syndromes of protein folding and oligomerization through the example of Alzheimer's disease is illustrated.
Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
The determination of the relationship between PrPC and AD and the characterization of PrPC binding to Aβ will facilitate the development of novel therapies for AD.
Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
Compelling evidence suggests the role of misfolded proteins in the form of oligomers might lead to synaptic dysfunction, neuronal apoptosis and brain damage, but the mechanism by which oligomers trigger neurodegeneration still remains mysterious.
Cellular Prion Protein and Amyloid – β Oligomers in Alzheimer's Disease – There Are Connections?
Several studies have shown that interaction of Aβ oligomers with N-terminal residues of the PrPc protein region appears critical for neuronal toxicity, and posttranslationally modifiedPrPc isoforms plays a fundamental role in AD pathological progression.
Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.
In Alzheimer's disease, insoluble and fibrillary amyloid-β (Aβ) peptide accumulates in plaques and receptors for Aβ oligomers are hypothesized to be the first step in a neuronal cascade leading to dementia.
The dynamic nature of amyloid-beta protein aggregation and its association to Alzheimer’s disease
The stoichiometry and the structure of the oligomers formed in the early stages of As aggregation are determined and it is demonstrated that As fibrils are in equilibrium with monomers and low molecular weight oligomers.
The role of amyloidogenic protein oligomerization in neurodegenerative disease
This review focuses on the potential role of amyloidogenic oligomers in neurodegenerative disease, highlighting some promising therapeutic strategies.


Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
The biochemical isolation of discrete amyloid-β moieties with pathophysiological properties sets the stage for a new approach to studying the molecular mechanisms of cognitive impairment in Alzheimer disease and related neurodegenerative disorders.
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
It is shown that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomer regardless of sequence, suggesting they share a common mechanism of toxicity.
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue and the rest of the disease process is proposed to result from an imbalance between Aβ production and Aβ clearance.
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
This article verifies the predicted accumulation of soluble oligomers in AD frontal cortex and confirms the prediction that soluble oligomeric Aβ ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
The shared 4-kDa subunit indicates a common origin for the amyloids of the plaque core and of the congophilic angiopathy of Alzheimer disease and Down syndrome.
A specific amyloid-β protein assembly in the brain impairs memory
It is found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which is proposed to be Aβ*56 (Aβ star 56), which may contribute to cognitive deficits associated with Alzheimer's disease.
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
An apparently full-length complementary DNA clone coding for the A4 polypeptide is isolated and sequenced and suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor.
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Aβ immunization reduces both deposition of cerebral fibrillar Aβ and cognitive dysfunction in the TgCRND8 murine model of Alzheimer's disease without, however, altering total levels of Aβ in the brain, which implies that either a ∼50% reduction in dense-cored Aβ plaques is sufficient to affect cognition, or that vaccination may modulate the activity/abundance of a small subpopulation of especially toxic Aβ species.
Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease
Plasma Aβ levels in a transgenic mouse model of Alzheimer's disease did not correlate with brain amyloid burden, but after peripheral administration of a monoclonal antibody to Aβ, there was a rapid increase in plasma Aβ and the magnitude of this increase was highly correlated with amyloids burden in the hippocampus and cortex.